Research programme: anti-matrix metalloproteinase monoclonal antibodies - Kadmon

Drug Profile

Research programme: anti-matrix metalloproteinase monoclonal antibodies - Kadmon

Alternative Names: DX-2400; DX-2802; KD-014

Latest Information Update: 29 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dyax
  • Developer Shire
  • Class Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 14 inhibitors; Matrix metalloproteinase 9 inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 21 Sep 2012 Preclinical development is ongoing in USA
  • 20 Sep 2012 DX 2400 licensed to Kadmon Corporation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top